-+ 0.00%
-+ 0.00%
-+ 0.00%

Egetis Therapeutics Agrees to Sell Priority Review Voucher for USD 190 Million

PUBT·11/04/2026 07:40:20
Egetis Therapeutics Agrees to Sell Priority Review Voucher for USD 190 Million
  • Egetis Therapeutics today agreed to sell its Rare Pediatric Disease Priority Review Voucher for USD 190 million, approximately SEK 1.9 billion.
  • Former owners of subsidiary Rare Thyroid Therapeutics International are entitled to approximately 50% of net proceeds under the 2020 EMCITATE acquisition earnout.
  • Closing remains subject to customary conditions, including expiration of the applicable Hart-Scott-Rodino antitrust waiting period.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Egetis Therapeutics AB (publ) published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.